KYBELLA® joins Allergan’s other widely known facial aesthetic products like BOTOX® Cosmetic, Juvéderm® XC, Juvéderm VOLUMA® XC and LATISSE®. Allergan is a leading global pharmaceutical company, and has been a trusted source for medical aesthetic products for years.
Have you looked in the mirror and felt self-conscious because of submental fullness, also known as a “double chin?” Perhaps you’ve even considered surgery to remove the excess fat in this area.
Submental fullness is a common, yet under treated condition that can create an aged look in both men and women. We are beyond excited to offer the first nonsurgical, FDA approved option to melt away the excess fat under your chin!
How does KYBELLA® work?
KYBELLA® consists of deoxycholic acid, which is a natural occurring molecule in the body. By injecting it into the subcutaneous fat in the chin area, it destroys the fat cells. Once destroyed, these cells cannot store or accumulate fat. This is exciting news for our patients who want to get rid of the fat that is stored in this area. The results are a contoured and firmer neckline and a more youthful appearance!
What to expect?
A KYBELLA® treatment is a noninvasive procedure consisting of multiple injections administered by one of Derma Health’s trained physicians. Treatments are performed in a relaxed, comfortable manner. KYBELLA® has proven to show results after the second visit, but for consistent, excellent results, we suggest a series of four to six treatments given approximately one month apart.
What are the side effects?
Some of the common side effects reported include bruising, swelling, pain, numbness, redness and areas of hardness in the treatment area.
Why Derma Health?
Derma Health only uses board certified doctors that have been highly trained to safely administer KYBELLA®. Since Derma Health is the leader in injectables such as BOTOX® and Juvéderm®, you can be confident that our doctors have the experience necessary to inject KYBELLA®, making this a safe procedure that requires little to no downtime.